Company: ABBV
Filing Date: 2025-02-20
Form Type: 424B5
Source: 0001104659-25-015715
Chunk: 7

Company: AbbVie Inc.
Filing Date: 2025-02-20
Form: 424B5
Chunk 7
---
 or in part, at any time and from time to time at the applicable redemption price set forth under the caption “ Description of Notes — Optional Redemption .”

Ranking

The Notes will be the Issuer’s unsecured, unsubordinated obligations, and will:

•

rank equally in right of payment with all of the Issuer’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations;

•

rank senior in right of payment to all of the Issuer’s future indebtedness that is subordinated to the Notes;

•

be effectively subordinated in right of payment to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the assets securing such indebtedness; and

•

be structurally subordinated in right of payment to all existing and future indebtedness, liabilities and other obligations of the Issuer’s subsidiaries.

Use of Proceeds

The Issuer expects the net proceeds to it from this offering will be approximately $3.97 billion (after deducting underwriting discounts and its estimated offering expenses). The Issuer intends to use the net proceeds from the sale of the Notes, together with cash on hand, (a) to repurchase, redeem, satisfy and discharge, defease, make a tender offer for, or otherwise repay at maturity (i) all of its 3.600%

<div align='center'>S-3</div>

TABLE OF CONTENTS

senior notes due 2025, which have a stated maturity date of May 14, 2025, in an aggregate outstanding principal amount of $3.750 billion, and/or (ii) all of its 3.800% senior notes due 2025, which have a stated maturity date of March 15, 2025, in an aggregate outstanding principal amount of $2.890 billion, and/or (iii) all of the 3.800% senior notes due 2025 of Allergan Funding SCS (formerly known as Actavis Funding SCS), which have a stated maturity date of March 15, 2025, in an aggregate principal amount of $130.225 million, and, in each case, to pay any premium and accrued and unpaid interest in respect thereof, and/or (b) for general corporate purposes.

Certain Covenants

The indenture governing the Notes includes covenants that, among other things, limit the ability of the Issuer and its subsidiaries to create or permit to exist mortgages with respect to their principal domestic properties and certain